The incidence of gastroesophageal cancer—encompassing gastric cancer, esophageal cancer, and gastroesophageal junction (GEJ) adenocarcinoma— continues to rise; however, treatment options remain limited. Targeted therapies, including Herceptin (Roche / Genentech / Chugai [for HER2-positive patients only]) and Cyramza (Eli Lilly), have been approved exclusively for gastric and GEJ adenocarcinoma patients across the major markets. Additional agents are also approved for later-line treatments in certain geographies, such as Keytruda (Merck & Co.), Opdivo (Bristol-Myers Squibb), and Lonsurf (Taiho). A plethora of agents including immunotherapies, vaccines, and a variety of targeted therapies are vying for approval in underserved patient segments, such as resectable disease or the first-line metastatic setting.

Questions Answered

  • How do current treatment practices differ among esophageal, gastric, and GEJ cancer patients? Do these practices differ by geography, and which populations provide the greatest drug-treatment opportunities?
  • What are interviewed experts’ insights on the use of currently approved agents? What clinical needs remain unfulfilled, and on what opportunities can developers capitalize?
  • Which drugs in late-phase development are poised to change the treatment landscape for gastroesophageal cancer? How are these agents being assessed, and how will they impact the gastroesophageal cancer market?
  • What are the key market drivers and constraints in the gastroesophageal market, and how will the market evolve over the forecast period?

Content Highlights

Geographies: United States, EU5, Japan.

Primary research: 20 country-specific interviews with thought-leading medical oncologists supported by survey data collected for this and other DRG research.

Epidemiology: Diagnosed and recurrent incidence of gastroesophageal cancer by country, segmented by HER2 status, histology, stage I-IV, and line of therapy.

Forecast: 10-year, annualized, drug-level sales and patient share of key gastroesophageal cancer therapies through 2028, segmented by brands / generics and market-relevant drug treatable populations.

Emerging therapies: Phase III: 12 drugs; Phase I / II: ~30 drugs.

Product Description

Disease Landscape & Forecast provides comprehensive market intelligence with world-class epidemiology, keen insight into current treatment paradigms, in-depth pipeline assessments, and drug forecasts supported by detailed primary and secondary research.

Table of contents

  • Disease Landscape & Forecast
    • Key Findings
    • Key Updates
      • December 2019
      • July 2019
      • May 2019
      • March 2019
      • December 2018
    • Market Outlook
      • Key Findings
      • Market Drivers and Constraints
        • What Factors Are Driving the Market for Gastroesophageal Cancer?
        • What Factors Are Constraining the Market for Gastroesophageal Cancer?
      • Segment-Specific Trends
        • Localized and Resectable Locally Advanced Gastroesophageal Cancer
        • Unresectable Locally Advanced Gastroesophageal Cancer
        • First-Line HER2-Negative Metastatic Gastric and Gastroesophageal Junction Adenocarcinoma
        • First-Line HER2-Positive Metastatic Gastric and Gastroesophageal Junction Adenocarcinoma
        • First-Line Metastatic Esophageal Cancer
        • Second-Line HER2-Negative Gastric and Gastroesophageal Junction Adenocarcinoma
        • Second-Line HER2-Positive Metastatic Gastric and Gastroesophageal Junction Adenocarcinoma
        • Second- and Third-Line Metastatic Esophageal Cancer
        • Third- and Fourth-Line Metastatic Gastric and Gastroesophageal Junction Adenocarcinoma
    • Forecast
      • Market Forecast Assumptions
      • Market Forecast Dashboard
    • Etiology and Pathophysiology
      • Disease Overview
      • Disease Pathophysiology
        • Anatomy of the Stomach and the Gastroesophageal Junction
        • Anatomy of the Esophagus
        • Histological Subtypes and Development of Gastric and Gastroesophageal Junction Adenocarcinoma
        • Histological Subtypes and Development of Esophageal Cancer
      • Staging and Classification
      • Key Pathways and Drug Targets
    • Epidemiology
      • Introduction
        • Key Findings
      • Epidemiology Populations
        • Diagnosed Incident Cases
        • Stage Distribution
        • Recurrent Incident Cases
        • Molecular Subtypes
        • Drug-Treatable Populations of Gastroesophageal Cancer
        • Drug-Treated Populations of Gastroesophageal Cancer
    • Current Treatment
      • Key Findings
      • Treatment Goals
      • Key Current Therapies
        • Overview
        • Angiogenesis Inhibitors
        • HER2 Inhibitors
        • Immune Checkpoint Inhibitors
        • Cytotoxic Agents
      • Medical Practice
        • Region-Specific Treatment Practices
    • Unmet Need Overview
      • Current and Future Attainment of Unmet Needs in Gastroesophageal Cancer
    • Emerging Therapies
      • Key Findings
      • Key Emerging Therapies
        • Immune Checkpoint Inhibitors
        • HER2 Inhibitors
        • Angiogenesis Inhibitors
        • PARP Inhibitors
        • Cytotoxic Agents
        • Claudin Inhibitors
        • FGFR Inhibitors
      • Early-Phase Pipeline Analysis
    • Access and Reimbursement Overview
      • Region-Specific Reimbursement Practices
        • United States
        • EU5
        • Japan
      • Looking for More?
    • Methodology
      • Bottom-Up Forecasting Overview
        • Patient Populations
        • Drug- and Regimen-Specific Assumptions
      • Bottom-Up Forecasting Assumptions
        • General Sources of Data
        • General Statements About Pricing
        • Dosing, Cycles of Therapy, and Compliance
        • Generic Erosion
        • Biosimilar Erosion
        • Out-Year Forecasting
        • Emerging Therapy Prices
      • Primary Market Research
        • Experts Interviewed
    • Appendix
      • Gastroesophageal Cancer Bibliography

Author(s): Ann-Marie Looney, M.Sc., Ph.D; Mudasir Khan, M.P.H

Ann-Marie Looney, is a Business Insights Analyst in the oncology team at Decision Resources Group. Prior to joining DRG, Dr Looney worked as a postdoctoral researcher for the National Children’s Research Centre and the Irish Centre for Fetal and Neonatal Translational Research, Ireland where her work centred on the discovery and validation of biomarkers of early childhood injury and disease, with a specific focus on early childhood obesity, neonatal brain injury and autism spectrum ; She has a in Neuroscience, a by research in molecular biology and a in clinical and translational research from University College Cork, Ireland.

Mudasir works as an associate epidemiologist within the epidemiology team at Decision Resources Group. He specializes in developing epidemiological forecasts for multiple indications within the DRG syndicated portfolio. Mudasir holds a masters in public health specializing in epidemiology from TISS, Mumbai.

Related Reports

Gastroesophageal Cancer | Geographic Focus - China | Gastric Cancer - China In-Depth - China

MARKET OUTLOOK China has the highest incidence of gastric cancer (gastric and gastroesophageal junction adenocarcinoma) in the world, and therapeutic options are limited...

View Details

Esophageal Cancer | Epidemiology | Extrapolated Worldwide Coverage

DRG’s extended worldwide coverage is the first and only evidence-based data set of epidemiological forecasts for key esophageal cancer pat...

View Details

Esophageal Cancer | Epidemiology | Epidemiology Dashboard

DRG Epidemiology’s coverage of esophageal cancer comprises epidemiological estimates of key patient populations in 45 countries worldwide. We report both the incidence and prevalence o...

View Details

Esophageal Cancer | Epidemiology | Emerging Markets

DRG Epidemiology's coverage of esophageal cancer comprises epidemiological estimates of key patient populations across 45 countries worldwide. We report both the incidence and prevalence of e...

View Details